Oxidative stress and Alzheimer's disease;Estrés oxidativo y enfermedad de Alzheimer

Revista de Neurologia

Volumn 42, Issue 7, 2006, Pages 419-427

  Jimenez Jimenez F J ^a,b   Alonso Navarro, H ^a   Ayuso Peralta, L ^a   Jabbour Wadih, T ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b NONE   (Spain)

Author keywords

Alzheimer; Central nervous system; Free radicals; Neuronal death; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; ANTIOXIDANT; COPPER ZINC SUPEROXIDE DISMUTASE; DNA; FREE RADICAL; LIPID; MANGANESE SUPEROXIDE DISMUTASE; NITRIC OXIDE; PROTEIN; SUPEROXIDE DISMUTASE; TRANSITION ELEMENT; AMYLOID BETA PROTEIN; HEME OXYGENASE; METAL; OXIDIZING AGENT;

AGING; ALZHEIMER DISEASE; BRAIN CELL; BRAIN MITOCHONDRION; CELL CULTURE; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; TRANSGENIC ANIMAL; ANIMAL; LIPID PEROXIDATION; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIOXIDANTS; HEME OXYGENASE (DECYCLIZING); HUMANS; LIPID PEROXIDATION; METALS; MITOCHONDRIA; NITRIC OXIDE; OXIDANTS; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 33750115853     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4207.2005225     Document Type: Review

References (178)

1. Halliwell B, Gutteridge JMC, Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med 1992; 119: 598-620.
2. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59: 1609-23.
3. Reiter RJ. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 1995; 9: 526-33.
4. Halliwell B, Gutteridge JMC. Lipid peroxidation, oxygen radicals, cell damage and antioxidant therapy. Lancet 1984; 1: 1396-8.
5. Halliwell B, Gutteridge JMC. Oxygen radicals and the nervous system. Trends Neurosci 1985; 8: 22-6.
6. Jiménez-Jiménez FJ, De Bustos F, Gasalla T, Ortí-Pareja M. Estrés oxidativo y sistema nervioso central. Neurología 1996; 11 (Supl 3): 13-22.
7. Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 1990; 55: 342-5.
8. Hajimohammadreza I, Brammer M. Brain membrane fluidity and lipid peroxidation in Alzheimer's disease. Neurosci Lett 1990; 112: 333-7.
9. Palmer AM, Burns MA. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res 1994; 645: 338-42.
10. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995; 45: 1594-601.
11. Marcus DL, Thomas C, Rodríguez C, Simberkoff K, Tsai JS, Strafaci JA, et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 1998; 150: 40-4.
12. DiCIero Miranda M, De Bruin VM, Vale MR, Viana GS. Lipid peroxidation and nitrite plus nitrate levels in brain tissue from patients with Alzheimer's disease. Gerontology 2000; 46: 179-84.
13. Karelson E, Bogdanovic N, Garlind A, Winblad B, Zilmer K, Kullisaar T, et al. The cerebrospinal areas in normal brain aging and in Alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense. Neurochem Res 2001; 26: 353-61.
14. Dei R, Takeda A, Niwa H, Li M, Nakagomi Y, Watanabe M, et al. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease. Acta Neuropathol (Berl) 2002; 104: 113-22.
15. Yu WF, Nordberg A, Ravid R, Guan ZZ. Correlation of oxidative stress and the loss of the nicotinic receptor alpha 4 subunit in the temporal cortex of patients with Alzheimer's disease. Neurosci Lett 2003; 338: 13-6.
16. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-hydroxynonenal-derived advanced lipid peroxidation and products are increased in Alzheimer's disease. J Neurochem 1997; 68: 2092-97.
17. Markesbery WR, Lovel MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998; 19: 33-6.
18. Gotz ME, Wacker M, Luckhaus C, Wanek P, Tatschner T, Jellinger K, et al. Unaltered brain levels of 1,N2-propanodeoxyguanosine adducts of trans-4-hydroxynonenal in Alzheimer's disease. Neurosci Lett 2002; 324: 49-52.
19. Pratico D, MY Lee V, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998; 12: 1777-83.
20. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J Neurochem 1997; 68: 2061-9.
21. Reich EE, Markesbery WR, Roberts LJ 2nd, Swift LL, Morrow JD, Montine TJ. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 2001; 158: 293-7.
22. Perry G, Castellani RJ, Smith MA, Harris PL, Kubat Z, Ghanbari K, et al. Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol (Berl) 2003; 106: 552-6.
23. Praprotnik D, Smith MA, Richey PL, VInters HV, Perry G. Plasma membrane fragility in dystrophic neuritis in senile plaques of Alzheimer's disease: an index of oxidative stress. Acta Neuropathol (Berl) 1996; 91: 1-5.
24. Mecocci P, Cherubini A, Beal MF, Cecchetti R, Chionne F, Polidori MC, et al. Altered mitochondrial membrane fluidity in AD brain. Neurosci Lett 1996; 207: 129-32.
25. Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, et al. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol 1997; 31: 53-64.
26. Prasad MR, Novell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipids alterations in Alzheimer's disease. Neurochem Res 1998; 23: 81-8.
27. Guan Z, Wang Y, Cairos NJ, Lantos PL, Dallner G, Sindelar PJ. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 1999; 58: 740-7.
28. Mulder C, Wahlund LO, Teerlink T, Blomberg M, Veerhuis R, Van Kamp GJ, et al. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J Neural Transm 2003; 110: 949-55.
29. Montine TJ, Huang DY, Valentine WM, Amarnath V, Saunders A, Weisgraber KH, et al. Crosslinking of apolipoprotein E by products of lipid peroxidation. J Neuropathol Exp Neurol 1996; 55: 202-10.
30. Pratico D, Urdu K, Leight S, Trojanowski JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001; 21: 4183-7.
31. Novell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 1997; 18: 457-61.
32. Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, Petersen RC, Kokmen E. No evidence for systemic oxidant stress in Parkinson's and Alzheimer's disease. Mov Disord 1995; 10: 566-73.
33. Ceballos-Picot I, Merad-Boudia M, Nicole A, Thevenin M, Hellier G, Legrain S, Berr C. Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type: place of the extracellular glutathione peroxidase. Free Radic Biol Med 1996; 20: 579-87.
34. McGrath LT, McGleenon BM, Brennan S, McColl D, McIlroy S, Passmore AP. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 2001; 94: 485-90.
35. Bourdel-Marchasson I, Delmas-Beavieux MC, Peuchant E, Richard-Harston S, Decamps A, Reignier B, et al. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001; 30: 235-41.
36. Ozcankaya R, Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J 2002; 43: 28-32.
37. Polidori MC, Mecocci P. Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis 2002; 4: 517-22.
38. Feillet-Coudray C, Tourtauchaux R, Niculescu M, Rock E, Tauveron I, Alexandr-Gouabau MC, et al. Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic BIol Med 1999; 27: 463-9.
39. Ihara Y, Hayabara T, Sasaki K, Fujisawa Y, Kawada R, Yamamoto T, et al. Free radicals and superoxide dismutase in blood of patients with Alzheimer's disease and vascular dementia. J Neurol Sci 1997; 153: 76-81.
40. Bermejo P, Gómez-Serranillos P, Santos J, Pastor E, Gil P, Martín-Aragón S. Determination of malonaldehyde in Alzheimer's disease: a comparative study of high-performance liquid chromatography and thiobarbituric acid test. Gerontology 1997; 43: 218-22.
41. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002; 59: 972-76.
42. Carney JM, Smith CD, Carney AM, Butterfield DA. Aging and oxygen-induced modifications in brain biochemistry and behavior. Ann NY Acad Sci 1994; 738: 44-53.
43. Hensley K, Hall N, Suramanian R, Cole P, Harris M, Aksenov M. et al. Brain regional correspondence between Alzheimer's disease histo pathology and biomarkers of protein oxidation. J Neurochem 1995; 65: 2146-56.
44. Aksenova MV, Aksenow MY, Payne RM, Trojanowski JQ, Schmidt ML, Carney JM, et al. Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders. Dement Geriatr Cogn Disord 1999; 10: 158-65.
45. Gabbita SP, Aksenov MY, Novell MA, Markesbery WR. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J Neurochem 1999; 73: 1660-6.
46. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 2001; 103: 373-83.
47. Korolainen MA, Goldsteins G, Alafuzoff I, Koistinaho J, Pirttila T. Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis 2002; 23: 3428-33.
48. Smith MA, Sayre LM, Anderson VE, Harris PL, Beal MF, Kowall N, et al. Cytochemical demonstration of oxidative damage in Alzheimer's disease by immunochemical enhancement of the carbonyl reaction with 2,2- dynitrophenylhydrazine. J Histochem Cytochem 1998; 46: 731-5.
49. Balcz B, Kirchner L, Cairns N, Fountoulakis M, Lubec G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm 2001; 61 (Suppl): S193-201.
50. Shuvaev VV, Laffont I, Serot JM, Fujii J, Taniguchi N, Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging 2001; 22: 397-402.
51. Gasic-Milenkovic J, Loske C, Munich G. Advanced glycation endproducts cause lipid peroxidation in the human neuronal cell line SH-SY5Y. J Alzheimer Dis 2003; 5: 25-30.
52. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994; 36: 747 51.
53. Gabbitta SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 1998; 71: 2034-40.
54. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 759-67.
55. Iida T, Furuta A, Nishioka K, Nakabeppu Y, Iwaki T. Expression of 8-oxoguanine DNA glucosylase is reduced and associated with neurofibrillary tangles in Alzheimer's disease brain. Acta Neuropathol (Berl) 2002; 103: 20-5.
56. Te Koppele JM, Lucassen PJ, Sakkee AN, Van Asten JG, Ravid R, Swaab DF, et al. 8OHdG levels in brain do not indicate oxidative DNA damage in Alzheimer's disease. Neurobiol Aging 1996; 17: 819-26.
57. Mecocci P, Polidori MC, Ingegni T, Cherubini A, Chionne F, Cecchetti R, et al. Oxidative damage to DNA in lymphocytes from AD patients. Neurology 1998; 51: 1014-7.
58. Morocz M, Kalman J, Juhasz A, Sinko I, McGlynn AP, Downes CS, et al. Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. Neurobiol Aging 2002; 23: 47-53.
59. Meccocci P, Polidori MC, Cherubini A, Ingegni T, Mattioli P, Catani M, et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 2002; 59: 794-8.
60. Lahiri DK, Xy Y, Klaunig J, Baiyewu O, Ogunniyi A, Hall K, et al. Effect of oxidative stress on DNA damage and beta-amyloid precursor proteins in lymphoblastoid cell lines from a Nigerian population. Ann NY Acad Sci 1999; 893: 331-6.
61. Lovell MA, Gabbita SP, Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 1999; 72: 771-6.
62. Lovell MA, Markesbery WR. Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch Neurol 2001; 58: 392-6.
63. Abe T, Tohgi H, Isobe C, Murrata T, Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res 2002; 70: 447-50.
64. Hermon M, Cairns N, Egly JM, Fery A, Dabudova O, Lubec G. Expression of DNA excision-repair-cross-complementing proteins p80 and p89 in brain of patients with Down syndrome and Alzheimer's disease. Neurosci Lett 1998; 251: 45-8.
65. Tan Z, Sun N, Schreiber SS. Immunohistochemical localization of redox factor-1 (Ref-1) in Alzheimer's hippocampus. Neuroreport 1998; 9: 2749-52.
66. Love S, Barber R, Wilcock GK. Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain 1999; 122: 247-53.
67. Morris CM, Kerwin JM, Edwardson JA. Non haem iron histochemistry of the normal and Alzheimer's disease hippocampus. Neurodegeneration 1994; 3: 267-75.
68. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 1990; 2: 327-40.
69. Youdim MBH. Iron in the brain: implications for Parkinson's and Alzheimer's disease. Mt Sinai J Med 1988; 55: 97-101.
70. Good PF, Perl DP, Bierer LM, Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol 1992; 31: 286-92.
71. Pappolla MA, Omar RA, Kim KS, Robakis NK. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am J Pathol 1992; 140: 621-28.
72. Watt F. Nuclear microscope analysis in Alzheimer's and Parkinson's disease: a review. Cell Mol Biol (Noisy-le-Grand) 1996; 42: 17-26.
73. Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease. Cell Mol Biol (Noisy-le-Grand) 2000; 46: 821-33.
74. Van Rensburg SJ, Carstens ME, Potocnik FC, Aucamp AK, Taljaard JJ. Increased frequency of the transferrin C2 subtype in Alzheimer's disease. Neuroreport 1993; 4: 1269-71.
75. Van Rensburg SJ, Carstens ME, Potocnik FC, Van der Spuy G, Van der Walt BJ, Taljaard JJ. Transferrin C2 and Alzheimer's disease: another piece of the puzzle found? Med Hypotheses 1995; 44: 268-72.
76. Smith MA, Wehr K, Harris PL, Siedlak SL, Connor JR, Perry G. Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res 1998; 788: 232-6.
77. Molina JA, Jiménez-Jiménez FJ, Aguilar MV, Meseguer I, Mateos-Vega CJ, González-Muñoz MJ, et al. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J Neural Transm 1998; 105: 479-88.
78. Loeffler DA, DeMaggio AJ, Juneau PL, Brickman CM, Mashour GA, Finkelman JH, et al. Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis Assoc Disord 1994; 8: 190-7.
79. Connor JR, Tucker P, Johnson M, Snyder B. Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease. Neurosci Lett 1993; 159: 88-90.
80. Loeffler DA, LeWitt PA, Juneau PL, Sima AA, Nguyen HU, DeMaggio AJ, et al. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res 1996; 738: 265-74.
81. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci 1996; 143: 137-42.
82. Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 1998; 19: 339-45.
83. Squitti R, Lupoi D, Pasqueletti P, Dal Forno G, Vernieri F, Chiovenda P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 2002; 59: 1153-61.
84. Evans PH, Klinowski J, Yano E, Urano N. Alzheimer's disease: a pathogenic role for aluminosilicate-induced phagocytic free radicals. Free Radic Res Commun 1989; 6: 317-21.
85. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 1994; 145: 42-7.
86. Schipper HM, Cisse S, Stopa EG. Expression of heme oxygenase-1 in the senescent and Alzheimer's-diseased brain. Ann Neurol 1995; 37: 758-68.
87. Takahashi M, Snyder SH. Interaction of amyloid precursor proteins and heme oxygenase. Alzheimer Dis Assoc Disord 2000; 14 (Suppl) 1: S67-71.
88. Takahishi M, Dore S, Ferris CD, Tomita T, Sawa A, Wolosker H, et al. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron 2000; 28: 461-73.
89. Ham D, Schipper HM. Heme oxygenase-1 induction and mitochondrial iron sequestration I astroglia exposed to amyloid peptides. Cell Moll Biol 2000; 46: 587-96.
90. Navarro JA, Molina JA, Jiménez-Jiménez FJ, Benito-León J, Ortí-Pareja M, Gasalla T, et al. Cerebrospinal fluid nitrate levels in patients with Alzheimer's disease. Acta Neurol Scand 1996; 94: 411-4.
91. Good PF, Werner P, Hay A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996; 149: 21-8.
92. Smith MA, Richey Haris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997; 17: 2653-7.
93. Luth HJ, Munch G, Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 2002; 953: 135-43.
94. Wong A, Luth HJ, Deuther-Conrad W, Dukic-Stefanovic S, Gasic-Milenkovic J, Arendt T, et al. Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Res 2001; 920: 32-40.
95. Williamson KS, Gabbita SP, Mou S, West M, Pye QN, Markesbery WR, et al. The nitration product 5-nitro-gamma-tochopherol is increased in the Alzheimer brain. Nitric Oxide 2002; 6: 221-7.
96. Smith MA, Vasak M, Knipp M, Castellani RJ, Perry G. Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease. Free Radic Biol Med 1998; 25: 898-902.
97. Abe T, Tohgi H, Murata T, Isobe C, Sato C. Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett 2001; 312: 177-9.
98. Mulder C, Wahlund LO, Blomberg M, De Jong S, van Kamp GJ, Scheltens P, et al. Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid. J Neural Transm 2002; 109: 1203-8.
99. Vitek MP, Snell J, Dawson H, Colton CA. Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloidbeta peptide. Biochem Biophys Res Commun 1997; 240: 391-4.
100. Akama KT, Albanese C, Pestell RG, Van Eldik LJ. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFκB-dependent mechanism. Proc Natl Acad Sci USA 1998; 95: 5795-800.
101. Getchell ML, Shah DS, Buch SK, Davis DG, Getchell TV. 3-nitrotyrosine immunoreactivity in olfactory receptor neurons of patients with Alzheimer's disease: implications for impaired odor sensitivity. Neurobiol Aging 2003; 24: 663-73.
102. Saura J, Luque JM, Cesura AM, Da Prada M, Chan Palay V, Huber G, et al. Increased monoamine oxidase B activity in plaque associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 1994; 62: 15 30.
103. Chen L, Richardson JS, Caldwell JE, Ang LC. Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer's disease and from nondemented controls. Int J Neurosci 1994; 75: 83 90.
104. Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I, et al. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 1995; 64: 1216 23.
105. Aksenov MY, Tucker HM, Nair P, Aksenova MV, Butterfield DA, Estus S, Markesbery WR. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. J Mol Neurosci 1998; 11: 151-64.
106. Furuta A, Price DL, Pardo CA, Troncoso JC, Xu ZS, Taniguchi N, et al. Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol 1995; 146: 357-67.
107. Lovell MA, Xie C, Markesbery WR. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 1998; 51: 1562-6.
108. Aksenov MY, Markesbery WR. Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease. Neurosci Lett 2001; 302: 141-5.
109. McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, et al. Alzheimer's disease and total plasma aminothiols. Biol Psychiatry 2003; 53: 254-60.
110. Konings CH, Kuiper MA, Teerlink T, Mulder C, Scheltens P, Wolters EC. Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease, and multiple system atrophy. J Neurol Sci 1999; 168: 112-5.
111. Cecchi C, Latorraca S, Sorbi S, Iantomasi T, Favilli F, Vincenzini MT, et al. Glutathione level is altered in lymphoblasts from patients with familial Alzheimer's disease. Neurosci Lett 1999; 275: 152-4.
112. Repetto MG, Reides CG, Evelson P, Kohan S, De Lustig ES, Llesuy SF. Peripheral markers of oxidative stress in probable Alzheimer patients. Eur J Clin Invest 1999; 29: 643-9.
113. Meseguer I, Molina JA, Jiménez-Jiménez FJ, Aguilar MV, Mateos-Vega CJ, González-Muñoz MJ, et al. Cerebrospinal fluid levels of selenium in patients with Alzheimer's disease. J Neural Transm 1999; 106: 309-15.
114. Famulari AL, Marschoff EF, Llesuy SF, Kohan S, Serra JA, Domínguez RO, et al. The antioxidant enzymatic blood profile in Alzheimer's and vascular diseases. Their association and a possible assay to differentiate demented subjects and controls. J Neurol Sci 1996, 141: 69-78.
115. Thome J, Gsell W, Rosler M, Kornhuber J, Frolich L, Hashimoto E, et al. Oxidative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimer's disease. Life Sci 1997; 60: 13-19.
116. De Leo ME, Borrello W, Passantino M, Palazzotti B, Mordente A, Daniele A, et al. Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer's disease. Neurosci Lett 1998; 250: 173-6.
117. Kulkarni-Narla A, Getchell TV, Schmitt FA, Getchell ML. Manganese and copper-zinc superoxide dismutases in the human olfactory mucosa: increased immunoreactivity in Alzheimer's disease. Exp Neurol 1996; 140: 115-25.
118. Tohgi H, Abe T, Nakanishi M, Hamato F, Sasaki K, Takahashi S. Concentrations of alpha tocopherol and its quinone derivative in cerebrospinal fluid from patients with vascular dementia of the Binswanger type and Alzheimer type dementia. Neurosci Lett 1994; 174: 73-6.
119. Jiménez-Jiménez FJ, De Bustos F, Molina JA, Benito-León J, Tallón-Barranco A, Gasalla T, et al. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease. J Neural Transm 1997; 104: 703-10.
120. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry 1998; 13: 840-5.
121. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003; 24: 915-9.
122. Jiménez-Jiménez FJ, Molina JA, De Bustos F, Ortí-Pareja M, Benito-León J, Tallón-Barranco A, et al. Serum levels of beta-carotene, alphacarotene and vitamin A in patients with Alzheimer's disease. Eur J Neurol 1999; 6: 495-7.
123. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 121-6.
124. Edlund C, Soderberg M, Kristensson K. Isoprenoids in aging and neurodegeneration. Neurochem Int 1994; 25: 35-8.
125. De Bustos F, Molina JA, Jiménez-Jiménez FJ, García-Redondo A, Gómez-Escalonilla C, Porta-Etessam J, et al. Serum levels of coenzyme Q10 in patients with Alzheimer's disease. J Neural Transm 2000; 107: 233-9.
126. Lovell MA, Xie C, Gabbita SP, Markesbery WR. Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic Biol Med 2000; 28: 418-27.
127. Raina AK, Templeton DJ, Deak JC, Perry G, Smith MA. Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease. Redox Rep 1999; 4: 23-7.
128. Wang Y, Santa-Cruz K, DeCarli C, Johnson JA. NAD(P)H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Alzheimer's disease. Neurobiol Aging 2000; 21: 525-31.
129. SantaCruz KS, Yazlovitskaya E, Collins J, Johnson J, DeCarli C. Regional NAP(P)H:quinone oxidoreductase activity in Alzheimer's disease. Neurobiol Aging 2004; 25: 63-9.
130. Kish SJ, Bergeron C, Rajput A, Dozic C, Mastrogiano F, Chang LG, et al. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 1992; 59: 776-9.
131. Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 1994; 63: 2179-84.
132. Parker WD, Parks J, Filley CM, Kleinschmidt-De Masters BK. Electron transport chain defects in Alzheimer's disease brain. Neurology 1994; 44: 1090-6.
133. Parker WD, Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990; 40: 1302-3.
134. Parker WD, Mahr NJ, Filley CM, Parks JK, Hughes D, Young DA, et al. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology 1994; 44: 1086.
135. Blanchard BJ, Park T, Fripp WJ, Lerman LS, Ingram VM. A mitochondrial DNA deletion in normally aging and in Alzheimer brain tissue. NeuroReport 1993; 4: 799-802.
136. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, McKee AC, Beal MF, et al. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics 1994; 23: 471-6.
137. Petruzella V, Chen X, Schon EA. Is a point mutation in the mitochondrial ND2 gene associated with Alzheimer's disease? Biochem Biophys Res Commun 1992; 186: 491-7.
138. Lin FH, Lin R. A comparison of single nucleotide primer extension with mispairing PCR-RLFP in detecting a point mutation. Biochem Biophys Res Commun 1992; 189: 1202-6.
139. Kosel S, Egensperger R, Mehraein P, Graeber MB. No association of mutations at nucleotide 5460 of mitochondrial NADH dehydrogenase with Alzheimer's disease. Biochem Biophys Res Commun 1994; 203: 745-9.
140. Van Zuylen AJ, Bosman GJCGM, Ruitenbeek W, Van Kalmthout PJC, De Grip WJ. No evidence for reduced thrombocyte cytochrome oxidase activity in Alzheimer's disease. Neurology 1992; 42: 1246-7.
141. Molina JA, De Bustos F, Jiménez-Jiménez FJ, Benito León J, Gasalla T, Ortí-Pareja M, et al. Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from Alzheimer's disease. Neurology 1997; 48: 636-8.
142. Chandrasekaran K, Giordano T, Brady DR, Stoll J, Martin LJ, Rapoport SI. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer's disease. Mol Brain Res 1994; 24: 336-40.
143. Simonian NA, Hyman BT. Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in hippocampal formation. J Neuropathol Exp Neurol 1993; 52: 580-5.
144. Bennett MC, Diamond DM, Stryker SL, Parks JK, Parker WD Jr. Cytochrome oxidase inhibition: a novel animal model of Alzheimer's disease. J Geriatr Psychiatry Neurol 1992; 5: 93-101.
145. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennet JP, et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 1997; 49: 918-25.
146. Chang SW, Zhang D, Chung HD, Zassenhaus HP. The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer's brain. Biochem Biophys Res Commun 2000; 273: 203-8.
147. Simon DK, Lin MT, Ahn CH, Liu GJ, Gibson GE, Beal MF, et al. Low mutational burden of individual acquired mitochondrial DNA mutations in brain. Genomics 2001; 73: 113-6.
148. Carrieri G, Bonafe M, De Luca M, Rose G, Varcasia O, Bruni A, et al. Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. Hum Genet 2001; 108: 194-8.
149. Cafe C, Torri C, Bertorelli L, Angeretti N, Lucca E, Forloni G, et al. Oxidative stress after acute and chronic application of beta-amyloid fragment 25-35 in cortical cultures. Neurosci Lett 1996; 203: 61-5.
150. Sopher BL, Fukuchi K, Kavanagh TJ, Furlong CE, Martin GM. Neurodegenerative mechanisms in Alzheimer disease. A role for oxidative damage in amyloid beta protein precursor-mediated cell death. Mol Chem Neuropathol 1996; 29: 153-68.
151. Yatin SM, Varadarajan S, Link CD, Butterfield DA. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol Aging 1999; 20: 325-30.
152. Brera B, Serrano A, De Ceballos ML. Beta-amyloid peptides are cytotoxic to astrocytes in culture: a role for oxidative stress. Neurobiol Dis 2000; 7: 395-405.
153. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation an its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002; 23: 655-64.
154. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1995; 1: 693-9.
155. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, et al. The Abeta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999; 38: 7609-16.
156. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, et al. Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999; 274: 37111-6.
157. Bozner P, Grishko V, LeDoux SP, Wilson GL, Chyan YC, Pappolla MA. The amyloid beta protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol 1997; 56: 1356-62.
158. Vélez-Pardo C, Ospina GG, Jiménez del Río M. Abeta(25-35) peptide and iron promote apoptosis in lymphocytes by an oxidative stress mechanism: involvement of H2O2, caspase-3, NF-kappaB, p53 and c-Jun. Neurotoxicology 2002; 23: 351-65.
159. Tamagno E, Robino G; Obbili A, Bardini P, Aragno M, Parola M, Danni O. H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol 2003; 180: 144-55.
160. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998; 70: 2212-5.
161. Matsuoka Y, Picciano M, La Francois J, Duff K. Fibrillar beta-amyloid evokes oxidative damage in a transgenic Mohs model of Alzheimer's disease. Neuroscience 2001; 104: 609-13.
162. Drake J, Link CD, Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model Neurobiol Aging 2003; 24: 415-20.
163. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 1998; 152: 871-7.
164. LaFontaine MA, Mattson MP, Butterfield DA. Oxidative stress in synaptosomal proteins from mutant presenilin-1 knock-in mice: implications for familial Alzheimer's disease. Neurochem Res 2002; 27: 417-21.
165. Yamada M, Tanaka T, Han D, Senzaki K, Kameyama T, Nabeshima T. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur J Neurosci 1999; 11: 83-90.
166. Yatin SM, Aksenov M, Butterfield DA. The antioxidant vitamin E modulates amyloid beta-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Neurochem Res 1999; 24: 427-35.
167. Eckert A, Steiner B, Marques C, Leutz S, Romig H, Haass C, et al. Elevated vulnerability to oxidative stress-induced cell death and activation of caspase-3 by the Swedish amyloid precursor protein mutation. J Neurosci Res 2001; 64: 183-92.
168. Russell RL, Siedlak SL, Raina AK, Bautista JM, Smith MA, Perry G. Increased neuronal glucose-6-phosphatase dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys 1999; 370: 236-9.
169. Martins RN, Harper CG, Stokes GB, Masters CL. Increased cerebral glucose-6-phosphatase dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 1986; 46: 1042-5.
170. Gibson GE, Sheu KF, Blass JP. Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Transm 1998; 105: 855-70.
171. Omar R, Pappolla M, Argain I, Davis K. Acid phosphatase activity in senile plaques and cerebrospinal fluid of patients with Alzheimer's disease. Arch Pathol Lab Med 1993; 117: 166-9.
172. Kimpara T, Takeda A, Yamaguchi T, Arai H, Okita N, Takase S, et al. Increased bilirubins and their derivatives in cerebrospinal fluid in Alzheimer's disease. Neurobiol Aging 2000; 21: 551-4.
173. Migheli A, Cavalla P, Piva R, Giordana MT, Schiffer D. Bcl-2 protein expression in aged brain and neurodegenerative diseases. Neuroreport 1994; 5: 1906-8.
174. Luetjens CM, Lankiewicz S, Bui NT, Krohn AJ, Poppe M, Prehn JH. Up-regulation of Bcl-xL in response to subtoxic beta-amyloid: role in neuronal resistance against apoptotic and oxidative injury. Neuroscience 2001; 102: 139-50.
175. Fernandes B, Proenca MT, Nogueira AJ, Grazina MM, Oliveira LM, Fernandes AI, et al. Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients. Int J Mol Med 1999; 4: 179-86.
176. Lauderback CM, Kanski J, Hackett JM, Maeda N, Kindy MS, Butterfield DA. Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res 2002; 924: 90-7.
177. Ramassamy C, Krzywkowski P, Averill D, Lussier-Cacan S, Theroux L, Christen Y, et al. Impact of apoE deficiency on oxidative insults and antioxidant levels in the brain. Brain Res Mol Brain Res 2001; 86: 76-83.
178. Colton CA, Brown CM, Cook D, Needham LK, Xu Q, Czapiga M, et al. ApoE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging 2002; 23: 777-85.